KR102958344B1 - R-chop와 병용되는 치다마이드의 활용 및 약물 조합 - Google Patents

R-chop와 병용되는 치다마이드의 활용 및 약물 조합

Info

Publication number
KR102958344B1
KR102958344B1 KR1020217018968A KR20217018968A KR102958344B1 KR 102958344 B1 KR102958344 B1 KR 102958344B1 KR 1020217018968 A KR1020217018968 A KR 1020217018968A KR 20217018968 A KR20217018968 A KR 20217018968A KR 102958344 B1 KR102958344 B1 KR 102958344B1
Authority
KR
South Korea
Prior art keywords
chidamide
chop
combination
treatment
cell lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217018968A
Other languages
English (en)
Korean (ko)
Other versions
KR20210104059A (ko
Inventor
시안핑 루
웨일리 자오
신 퓨
펭펭 수
팅 리우
Original Assignee
쉔젠 칩스크린 바이오사이언스 씨오., 엘티디.
루이진 호스피탈, 상하이 지아오통 유니버시티 스쿨 오브 메디슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디., 루이진 호스피탈, 상하이 지아오통 유니버시티 스쿨 오브 메디슨 filed Critical 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디.
Publication of KR20210104059A publication Critical patent/KR20210104059A/ko
Application granted granted Critical
Publication of KR102958344B1 publication Critical patent/KR102958344B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217018968A 2018-11-20 2019-11-18 R-chop와 병용되는 치다마이드의 활용 및 약물 조합 Active KR102958344B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811394614.7 2018-11-20
CN201811394614 2018-11-20
PCT/CN2019/119170 WO2020103788A1 (zh) 2018-11-20 2019-11-18 西达本胺联合r-chop的应用及联合药物

Publications (2)

Publication Number Publication Date
KR20210104059A KR20210104059A (ko) 2021-08-24
KR102958344B1 true KR102958344B1 (ko) 2026-04-29

Family

ID=70741744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217018968A Active KR102958344B1 (ko) 2018-11-20 2019-11-18 R-chop와 병용되는 치다마이드의 활용 및 약물 조합

Country Status (12)

Country Link
US (1) US12194054B2 (cg-RX-API-DMAC7.html)
EP (1) EP3884943B1 (cg-RX-API-DMAC7.html)
JP (1) JP7489397B2 (cg-RX-API-DMAC7.html)
KR (1) KR102958344B1 (cg-RX-API-DMAC7.html)
CN (2) CN111195249B (cg-RX-API-DMAC7.html)
AU (1) AU2019385373B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009627A2 (cg-RX-API-DMAC7.html)
MY (1) MY209036A (cg-RX-API-DMAC7.html)
PH (1) PH12021551138A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105137RA (cg-RX-API-DMAC7.html)
TW (1) TWI768263B (cg-RX-API-DMAC7.html)
WO (1) WO2020103788A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113813268A (zh) * 2020-06-18 2021-12-21 苏州亚盛药业有限公司 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途
CN112274509B (zh) * 2020-12-02 2022-04-26 四川大学华西医院 西达本胺联合bcl2抑制剂在双表达型b细胞淋巴瘤中的应用
CN118593502B (zh) * 2024-05-24 2026-08-04 厦门大学附属第一医院 一种预防或治疗tp53突变双打击淋巴瘤的联合用药物组合物及其应用
CN121513004B (zh) * 2026-01-14 2026-04-03 首都医科大学附属北京友谊医院 一种治疗abc型弥漫性大b细胞淋巴瘤的组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
HRP20060080A2 (en) * 2003-08-26 2006-07-31 Sloan-Kettering Institute For Cancer Research Method of treating cancer with hdac inhibitors
CN101146548A (zh) * 2005-02-15 2008-03-19 诺华疫苗和诊断公司 化疗药、il-2和任选的抗cd20抗体联用治疗淋巴瘤的方法
CN101470112A (zh) * 2007-12-28 2009-07-01 上海交通大学医学院附属瑞金医院 弥漫性大b细胞淋巴瘤治疗指导和预后判断的分子标志物
CN103833626B (zh) 2012-11-27 2015-11-25 深圳微芯生物科技有限责任公司 西达本胺的晶型及其制备方法与应用
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
MX2019000864A (es) 2016-07-20 2019-06-03 Univ Columbia Activadores de histona acetiltransferasa y sus composiciones y usos.
CN107157978B (zh) * 2017-05-24 2021-06-18 中国药科大学 治疗ebv+dlbcl和dlbcl的药物及组合物
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blood 130 (2017): 4126*

Also Published As

Publication number Publication date
TW202033194A (zh) 2020-09-16
AU2019385373B2 (en) 2025-08-21
SG11202105137RA (en) 2021-06-29
CN111195249B (zh) 2023-11-28
KR20210104059A (ko) 2021-08-24
CA3120207A1 (en) 2020-05-28
US12194054B2 (en) 2025-01-14
JP2022511126A (ja) 2022-01-28
CN111195249A (zh) 2020-05-26
US20220016147A1 (en) 2022-01-20
EP3884943B1 (en) 2024-07-17
PH12021551138A1 (en) 2022-02-21
EP3884943A1 (en) 2021-09-29
JP7489397B2 (ja) 2024-05-23
EP3884943A4 (en) 2022-07-06
BR112021009627A2 (pt) 2021-08-10
MY209036A (en) 2025-06-17
CN117797149A (zh) 2024-04-02
WO2020103788A1 (zh) 2020-05-28
TWI768263B (zh) 2022-06-21
AU2019385373A1 (en) 2021-06-24
EP3884943C0 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
US12194054B2 (en) Application of Chidamide in combination with R-CHOP, and drug combination
Munakata et al. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
CN108883109A (zh) 用于治疗急性髓性白血病的联合疗法
Peterson et al. Intensive five‐drug combination chemotherapy for adult acute non‐lymphocytic leukemia
CN113908159A (zh) 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途
Oh et al. The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate
CA2944088C (en) Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
Hansen et al. Phase III study of intermittent 5‐drug regimen (VBCMP) versus intermittent 3‐drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis
Pelosi et al. The growing role of the BH3 mimetic drug venetoclax in the therapy of acute myeloid leukemia
CN107157978B (zh) 治疗ebv+dlbcl和dlbcl的药物及组合物
CA3120207C (en) Application of chidamide in combination with r-chop, and drug combination
RU2802620C2 (ru) Применение хидамида в комбинации с R-CHOP и комбинация лекарственных средств
HK40057612A (en) Application of chidamide in combination with r-chop, and drug combination
HK40057612B (en) Application of chidamide in combination with r-chop, and drug combination
CN111228264A (zh) 西达本胺联合cgb以及自体造血干细胞的应用及联合药物
US20110301102A1 (en) Compositions and methods for treating myelodysplastic syndrome
CN111195250A (zh) 西达本胺联合dice的应用及联合药物
US20240277663A1 (en) Pharmaceutical kits and uses thereof for treating colorectal cancer
JP2012025734A (ja) 骨髄異形性症候群を治療するための組成物および方法
CA3190276A1 (en) Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
Zheng et al. Strategy to further increase of cure rate in acute promyelocytic leukaemia: low-dose all-trans retinoic acid and sequential maintenance cycle Correspondence.
MX2011009301A (es) Composiciones y metodos para tratar sindrome mielodisplasico.
Prescott Advances in the Treatment of Hematological Malignancies
WO2013019222A1 (en) Compositions and methods for treating myelodysplastic syndrome
Guida Rituximab in advanced rheumatoid arthritis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)